Prognostic Factors and Therapeutic Management of ESBL Enterobacteriaceae in the ICU

Recruiting

• Conditions: Drug Resistance, Multiple, Bacterial

• Registration Number: NCT05833282
• Lead Sponsor: Tourcoing Hospital

Brief Summary

Multicenter retrospective study conducted in the intensive care units of Tourcoing, Roubaix, and Lille hospitals. Patients hospitalized in the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU will be selected from microbiology laboratory data. Patient demographics and clinical data will be collected from the medical record. Microbiological results will be collected from the laboratory data.

Detailed Description

INCLUSION CRITERIA - Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

PRIMARY ENDPOINT

- The primary endpoint is 30-day mortality.

Study Timeline

• Study Start: 2022-07-01
• Status Verified: 2023-04
• Study First Submitted: 2023-04-04
• Study First Submitted QC: 2023-04-26
• Last Update Submitted: 2023-04-26
• Study First Posted: 2023-04-27
• Last Update Posted: 2023-04-27
• Primary Completion: 2023-06-30
• Study Completion: 2023-06-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

• Patients admitted to the ICU with EBLSE bacteremia within 24 hours before or during their stay in the ICU.

Exclusion Criteria

• Patient who is a minor, protected adult, or who refuses to participate.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The primary endpoint is all-cause 30-day mortality.	30-day mortality	all-cause mortality.

Secondary Outcome Measures

Name	Time	Method
Adequacy of initial antibiotic therapy to french recommendations	adequate within 30 days	Antibiotic prescriptions will be considered adequate if all of the following criteria meet the recommendations: molecule, dose, according to the recommendations provided by the French Society of Infectious Diseases. The recommendations for prescribing antibiotics are similar to those proposed by international guidelines.

Trial Locations

Locations (1)

Centre Hospitalier DRON; 🇫🇷 Tourcoing, France